Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
How MRD Status Is Being Used to Guide Myeloma Treatment Decisions | Ben Derman MD #IMS25
HealthTreeDescription
How is minimal residual disease (MRD) being used in real-world myeloma care? In this presentation from the International Myeloma Society (IMS) 2025 Annual Meeting (#IMS2025), Ben Derman, MD, discusses how MRD testing is shaping treatment decisions, guiding therapy duration, and helping both doctors and patients better understand response to treatment.
This important update highlights how MRD is moving from research into everyday patient care, giving doctors more precise ways to personalize myeloma treatment.
🔔 Subscribe to HealthTree for the latest insights from top myeloma experts and global conferences.
#Myeloma #MRD #IMS2025 #MyelomaResearch #HealthTree #BenDermanMD #CancerResearch
Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.